Literature DB >> 33562055

Semi-Automatic MRI Muscle Volumetry to Diagnose and Monitor Hereditary and Acquired Polyneuropathies.

Friederike S Bähr1, Burkhard Gess1, Madlaine Müller1,2, Sandro Romanzetti1, Michael Gadermayr3,4, Christiane Kuhl5, Sven Nebelung5,6, Jörg B Schulz1,7, Maike F Dohrn1,8.   

Abstract

With emerging treatment approaches, it is crucial to correctly diagnose and monitor hereditary and acquired polyneuropathies. This study aimed to assess the validity and accuracy of magnet resonance imaging (MRI)-based muscle volumetry.Using semi-automatic segmentations of upper- and lower leg muscles based on whole-body MRI and axial T1-weighted turbo spin-echo sequences, we compared and correlated muscle volumes, and clinical and neurophysiological parameters in demyelinating Charcot-Marie-Tooth disease (CMT) (n = 13), chronic inflammatory demyelinating polyneuropathy (CIDP) (n = 27), and other neuropathy (n = 17) patients.The muscle volumes of lower legs correlated with foot dorsiflexion strength (p < 0.0001), CMT Neuropathy Score 2 (p < 0.0001), early gait disorders (p = 0.0486), and in CIDP patients with tibial nerve conduction velocities (p = 0.0092). Lower (p = 0.0218) and upper (p = 0.0342) leg muscles were significantly larger in CIDP compared to CMT patients. At one-year follow-up (n = 15), leg muscle volumes showed no significant decrease.MRI muscle volumetry is a promising method to differentiate and characterize neuropathies in clinical practice.

Entities:  

Keywords:  CIDP; CMT; MRI; biomarker; muscle volume; neuropathy

Year:  2021        PMID: 33562055      PMCID: PMC7914808          DOI: 10.3390/brainsci11020202

Source DB:  PubMed          Journal:  Brain Sci        ISSN: 2076-3425


  35 in total

1.  Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

Authors:  Jeffrey A Allen; Deborah F Gelinas; Miriam Freimer; M Chris Runken; Gil I Wolfe
Journal:  J Neurol Sci       Date:  2019-11-09       Impact factor: 3.181

2.  Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Yusuf A Rajabally
Journal:  Muscle Nerve       Date:  2015-05       Impact factor: 3.217

3.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Ivo N van Schaik; Vera Bril; Nan van Geloven; Hans-Peter Hartung; Richard A Lewis; Gen Sobue; John-Philip Lawo; Michaela Praus; Orell Mielke; Billie L Durn; David R Cornblath; Ingemar S J Merkies
Journal:  Lancet Neurol       Date:  2017-11-06       Impact factor: 44.182

4.  Hippocampal atrophy based Alzheimer's disease diagnosis via machine learning methods.

Authors:  Gokce Uysal; Mahmut Ozturk
Journal:  J Neurosci Methods       Date:  2020-02-29       Impact factor: 2.390

5.  Epidemiology of chronic inflammatory neuropathies in southeast England.

Authors:  M Mahdi-Rogers; R A C Hughes
Journal:  Eur J Neurol       Date:  2013-05-17       Impact factor: 6.089

6.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

7.  Semi-automated volumetry of MRI serves as a biomarker in neuromuscular patients.

Authors:  Madlaine Müller; Maike F Dohrn; Sandro Romanzetti; Michael Gadermayr; Kathrin Reetz; Nils A Krämer; Christiane Kuhl; Jörg B Schulz; Burkhard Gess
Journal:  Muscle Nerve       Date:  2020-02-17       Impact factor: 3.217

Review 8.  NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment.

Authors:  Ana Fernandez-Marmiesse; Sofia Gouveia; Maria L Couce
Journal:  Curr Med Chem       Date:  2018-01-30       Impact factor: 4.530

9.  Image Analysis Reveals Microstructural and Volumetric Differences in Glioblastoma Patients with and without Preoperative Seizures.

Authors:  Stefanie Bette; Melanie Barz; Huong Ly Nham; Thomas Huber; Maria Berndt; Arthur Sales; Friederike Schmidt-Graf; Hanno S Meyer; Yu-Mi Ryang; Bernhard Meyer; Claus Zimmer; Jan S Kirschke; Benedikt Wiestler; Jens Gempt
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

10.  MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.

Authors:  Jasper M Morrow; Christopher D J Sinclair; Arne Fischmann; Pedro M Machado; Mary M Reilly; Tarek A Yousry; John S Thornton; Michael G Hanna
Journal:  Lancet Neurol       Date:  2015-11-06       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.